A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

• Published in: PloS one Vol. 10; no. 10; p. e0138348
• Main Authors: Greenberg, Richard N, Hurley, Yadira, Dinh, Dinh V., Mraz, Serena, Vera, Javier Gomez, von Bredow, Dorothea, von Krempelhuber, Alfred, Roesch, Siegfried, Virgin, Garth, Arndtz-Wiedemann, Nathaly, Meyer, Thomas Peter, Schmidt, Darja, Nichols, Richard, Young, Philip, Chaplin, Paul
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 06.10.2015; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Antibodies; Antibody Formation - immunology; Atopic dermatitis; Biological & chemical weapons; Clinical trials; Complications; Complications and side effects; Control; Dermatitis; Dermatitis, Atopic - immunology; Dermatitis, Atopic - prevention & control; Dermatology; Eczema; Heart diseases; HIV; Human immunodeficiency virus; Humans; Immune response (humoral); Immunogenicity; Infections; Physiological aspects; Population studies; Replicating; Replication; Safety; Safety and security measures; Seroconversion; Skin; Smallpox; Smallpox Vaccine - adverse effects; Smallpox Vaccine - standards; Smallpox Vaccine - therapeutic use; Smallpox vaccines; Vaccination; Vaccines; Vaccinia virus - immunology; Variola major; Viral Vaccines - adverse effects; Viral Vaccines - standards; Viral Vaccines - therapeutic use; Viruses; Young Adult; United States; Germany; Ankara Turkey; Mexico; Vallejo California; Turkey; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0138348

Replicating smallpox vaccines can cause severe complications in individuals with atopic dermatitis (AD). Prior studies evaluating Modified Vaccinia Ankara virus (MVA), a non-replicating vaccine in humans, showed a favorable safety and immunogenicity profile in healthy volunteers. This Phase II study compared the safety and immunogenicity of MVA enrolling groups of 350 subjects with AD (SCORAD ≤ 30) and 282 healthy subjects. Subjects were vaccinated twice with MVA, each dose given subcutaneously 4 weeks apart. Adverse events, cardiac parameters, and the development of vaccinia virus humoral immune responses were monitored. The overall safety of the vaccine was similar in both groups. Adverse events affecting skin were experienced significantly more often in subjects with AD, but the majority of these events were mild to moderate in intensity. Seroconversion rates and geometric mean titers for total and neutralizing vaccinia-specific antibodies in the AD group were non-inferior compared to the healthy subjects. The size of the study population limited the detection of serious adverse events occurring at a frequency less than 1%. MVA has a favorable safety profile and the ability to elicit vaccinia-specific immune responses in subjects with AD. ClinicalTrials.gov NCT00316602.